SiNtx Technologies

SINT

Valor de mercado US$ 13,2 mi

SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance  Revenue milestone also enables Company to call Class B warrants SALT LAKE CITY, Utah, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced preliminary, unaudited revenue of $2.2 million* for the third quarter ended September 30, 2026. The result exceeds the high end of the Company's previously announced guidance of $0.9 million to $1.1 million, reflecting stronger-than-expected industrial ceramics sales, and is expected to result in narrower losses than previous quarters.

Experts in implant retrieval, biomaterials and clinical practice examine the science, clinical experience and potential advantages of silicon nitride relative to established implant materials in Company-sponsored Orthopedics This Week Masterclass SALT LAKE CITY, Utah, Sept. 14, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced the availability of a Company-sponsored Masterclass hosted by Orthopedics This Week (“OTW”), the most widely read publication in the orthopedics industry, that brings together three industry experts to present arguments examining the value of silicon nitride over legacy implant materials and to increase awareness of the impact it may have in orthopedic applications.

SALT LAKE CITY, Utah, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced that it will participate in the 28th Annual H.C.

SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SALT LAKE CITY, Utah, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain minimum stockholders' equity of $2.5 million. Based on SINTX's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which reported stockholders' equity of approximately $4.83 million, Nasdaq determined that the Company complies with the minimum stockholders' equity requirement under Listing Rule 5550(b)(1) and confirmed that the previously disclosed deficiency matter is now closed.

Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript

SALT LAKE CITY, Utah, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today provided a business update in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. During the first half of 2026, SINTX advanced the commercialization of its FDA-cleared SiNAPTIC® Foot & Ankle Implant System, expanded its commercial distribution network, raised additional capital, invested in advanced manufacturing capabilities, and continued to broaden the application of its proprietary silicon nitride technology platform across multiple healthcare and industrial markets.

SALT LAKE CITY, Utah, July 28, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride ceramics and advanced material technologies, today announced that it will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after the market close. The Company will also host a conference call and webcast that day at 4:30 p.m.

SALT LAKE CITY, Utah, July 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced biomaterials and silicon nitride technologies for medical device and industrial applications, today announced that it has engaged Southern Metrics Consulting (“Southern Metrics”) to assist the Company in identifying, evaluating, and pursuing strategic opportunities intended to enhance stockholder value. Southern Metrics is led by Chris Lyons, its Chief Executive Officer, an experienced medical technology executive and strategic advisor who has served on the SINTX Board of Directors since April 2025. Southern Metrics will establish and manage the Company's newly created Strategic Opportunity Management Program.